

ASX Release
18 January 2024

ASX Code: MEM

Entitlement Offer Prospectus Completion

Pursuant to the pro-rata non-renounceable Entitlement Offer Prospectus dated 4 December 2023 and lodged with ASIC and ASX on same day, the following securities have been allotted today:

Shares issued to applicants:	54,305,732
Shortfall allotment:	158,922,042
Total allotment of shares:	213,227,774
Total shares on issue after allotment:	1,343,858,732

For further information please contact:

ENDS

For further information, please contact:

Dr David Ali
Interim Managing Director / Chief Executive Officer
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

Andrew Metcalfe
Company Secretary
Memphasys Limited
Tel: +61 412 125 090
E: andrew@accosec.com

About Memphasys

Memphasys Limited (ASX: MEM) specialises in reproductive biotechnology for high value commercial applications. Reproductive biotechnology products in development include medical devices, *in vitro* diagnostics, and new proprietary media. The Company's patented bio-separation technology, utilised by the Company's most advanced product, the Felix™ System device, combines electrophoresis with proprietary size exclusion membranes to separate the most viable sperm cells for human artificial reproduction.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.